eBioscience Corporation today announced that it has acquired privately held immunoassay technology pioneer Bender MedSystems GmbH in an all cash transaction. The acquisition will provide eBioscience with over 1,000 high profile immunology and oncology products including the Instant ELISA® and FlowCytomix(TM) brands that target the life sciences and diagnostics markets.
"Bender MedSystems provides us with a cutting-edge technology platform that, when combined with many of eBioscience's leading cell analysis research and diagnostic products, will facilitate the accelerated development and commercialization of breakthrough innovations," explained eBioscience CEO, Todd R. Nelson Ph.D. "Bender MedSystems proprietary Instant ELISA® technology and associated product lines confer several major competitive advantages over existing technologies including increased sensitivity, significantly simplified handling and reduced analysis time," added Michael Schaude Ph.D., CEO of Bender MedSystems.
Bender MedSystems' novel bead based multiplexing technology and products, marketed and sold under the FlowCytomix(TM) brand, allow researchers to analyze simultaneously up to 20 proteins in a single reaction. This highly scalable technology platform can be combined with many of eBioscience's existing technologies that the company intends to use in the development of a significant number of expanded sets of cell analysis product lines.